In Vivo: Administration of unlabeled AZD4694 to rat showed that it has a pharmacokinetic profile consistent with good PET radioligands, it quickly entered and rapidly cleared from normal rat brain tissue. AZD4694 (4 mL/kg; intravenous injection) inhibits [3H]AZD2184 binding (1 nM) in a concentration-dependent manner, with a Ki of 23.1 nM, in postmortem brain sections from AD patients.